Clinical TrialApr 21, 2026, 04:57 PM
Rapport Therapeutics RAP-219 Phase 2a Shows Sustained Seizure Reduction
AI Summary
Rapport Therapeutics announced positive results from the 8-week follow-up period of its Phase 2a trial for RAP-219 in focal onset seizures (FOS). The trial demonstrated sustained seizure reduction and continued biomarker and clinical responses. This sustained effect is attributed to RAP-219's long half-life, maintaining therapeutic levels post-treatment.
Key Highlights
- RAP-219 Phase 2a trial results for focal onset seizures announced.
- 8-week follow-up period showed sustained seizure reduction.
- Therapeutic levels of RAP-219 maintained due to long half-life.
- Continued biomarker and clinical responses observed.
Price Impact
More from RAPP